Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis. / Havers-Borgersen, Eva; Butt, Jawad H.; Vinding, Naja E.; Torp-Pedersen, Christian; Gislason, Gunnar; Køber, Lars; Fosbøl, Emil L.
In: Journal of Thoracic and Cardiovascular Surgery, Vol. 159, No. 1, 01.2020, p. 74-83.e4.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - Time in therapeutic range and risk of thromboembolism and bleeding in patients with a mechanical heart valve prosthesis
AU - Havers-Borgersen, Eva
AU - Butt, Jawad H.
AU - Vinding, Naja E.
AU - Torp-Pedersen, Christian
AU - Gislason, Gunnar
AU - Køber, Lars
AU - Fosbøl, Emil L.
PY - 2020/1
Y1 - 2020/1
N2 - Objective: Oral anticoagulation with vitamin K antagonists is recommended after mechanical heart valve replacement. However, data regarding the association between the quality of vitamin K antagonist treatment and the risk of complications are sparse. Methods: Patients undergoing mechanical heart valve replacement (1997-2012) with available data on international normalized ratio values were identified in Danish registries. The quality of vitamin K antagonist treatment between discharge after valve replacement and 6 months postdischarge (ie, index) was assessed as time in therapeutic range (TTR) ≥70% or <70% reflecting the percentage of time in therapeutic international normalized ratio interval. Patients were followed from index until occurrence of an outcome of interest (ie, thromboembolism and bleeding), death, or end of study (December 31, 2012), whichever came first. The risk of outcomes according to quality of vitamin K antagonist treatment was estimated with multivariable Cox regression. Results: In total, 659 patients undergoing mechanical heart valve replacement were included in the study. Median number of international normalized ratio measurements in the 6-month period after surgery was 13 (interquartile range, 8-19). Median TTR was 54.9% (interquartile range, 39.0%-72.9%) and 29.1% of patients had a TTR ≥70%. Median follow-up was 6.1 years. The risk of thromboembolism was significantly lower in the group with TTR ≥70% compared with TTR <70% (hazard ratio, 0.44; 95% confidence interval, 0.22-0.85), whereas no significant difference concerning risk of bleeding among groups was found (hazard ratio, 0.63; 95% confidence interval 0.36-1.08). Conclusions: In patients undergoing mechanical heart valve replacement, TTR <70% in the 6-month period after surgery was associated with an increased risk of thromboembolic events but not bleeding compared with TTR ≥70%.
AB - Objective: Oral anticoagulation with vitamin K antagonists is recommended after mechanical heart valve replacement. However, data regarding the association between the quality of vitamin K antagonist treatment and the risk of complications are sparse. Methods: Patients undergoing mechanical heart valve replacement (1997-2012) with available data on international normalized ratio values were identified in Danish registries. The quality of vitamin K antagonist treatment between discharge after valve replacement and 6 months postdischarge (ie, index) was assessed as time in therapeutic range (TTR) ≥70% or <70% reflecting the percentage of time in therapeutic international normalized ratio interval. Patients were followed from index until occurrence of an outcome of interest (ie, thromboembolism and bleeding), death, or end of study (December 31, 2012), whichever came first. The risk of outcomes according to quality of vitamin K antagonist treatment was estimated with multivariable Cox regression. Results: In total, 659 patients undergoing mechanical heart valve replacement were included in the study. Median number of international normalized ratio measurements in the 6-month period after surgery was 13 (interquartile range, 8-19). Median TTR was 54.9% (interquartile range, 39.0%-72.9%) and 29.1% of patients had a TTR ≥70%. Median follow-up was 6.1 years. The risk of thromboembolism was significantly lower in the group with TTR ≥70% compared with TTR <70% (hazard ratio, 0.44; 95% confidence interval, 0.22-0.85), whereas no significant difference concerning risk of bleeding among groups was found (hazard ratio, 0.63; 95% confidence interval 0.36-1.08). Conclusions: In patients undergoing mechanical heart valve replacement, TTR <70% in the 6-month period after surgery was associated with an increased risk of thromboembolic events but not bleeding compared with TTR ≥70%.
KW - epidemiology
KW - mechanical heart valve prostheses
KW - Nordic Medico-Statistical Committee
KW - oral anticoagulation
KW - time in therapeutic range
KW - vitamin K antagonists
U2 - 10.1016/j.jtcvs.2019.02.061
DO - 10.1016/j.jtcvs.2019.02.061
M3 - Journal article
C2 - 30961980
AN - SCOPUS:85063665016
VL - 159
SP - 74-83.e4
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
SN - 0022-5223
IS - 1
ER -
ID: 240241612